GlassScriptPhysician profile
Susan L Tan
NPI 1457731358
$3,471.49
in general payments reported to CMS, 2019-2025
12 companies · $2,005 in 2025
The $2,005 reported for 2025 was more than what 90% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $49.49 · 2021: $144 · 2022: $132 · 2023: $176 · 2024: $589 · 2025: $2,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,332 · Food and Beverage: $1,264 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,332.40 |
| Food and Beverage | $1,263.84 |
| Education | $173.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,469.02 | 2025 | Scopis Ent, Xpress Loprofile |
| Regeneron Healthcare Solutions, INC. | $403.60 | 2024-2025 | Dupixent |
| Intersect Ent, INC. | $320.40 | 2019-2022 | |
| Acclarent, INC | $233.72 | 2022-2024 | Relieva Spinplus, Acclarent Aera, Trudi Nav Cable |
| Glaxosmithkline, LLC. | $218.85 | 2024-2025 | Nucala |
| Genzyme Corporation | $153.33 | 2025 | |
| Merz North America, INC. | $152.23 | 2023 | Xeomin |
| Comsort, INC | $150.00 | 2019 | |
| Medtronic, INC. | $144.00 | 2022-2024 | Propel |
| Revance Therapeutics, INC. | $112.19 | 2024 | Daxxify |
| Smith+Nephew, INC. | $98.36 | 2019-2021 | |
| Travere Therapeutics, INC. | $15.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.